Trial Profile

A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2014 Status changed from recruiting to completed according to an EnGeneIC media release.
26 Mar 2013 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com